1
Kangawa Kenji, Kojima Masayasu, Hosoda Hiroshi, Matsuo Hisayuki, Minamitake Yoshiharu: Novel peptides. Kangawa Kenji, April 17, 2002: EP1197496-A1 (25 worldwide citation)

The present invention provides a novel peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pha ...


2
Kitamura Kazuo, Kangawa Kenji, Matsuo Hisayuki, Eto Tanenao: Adrenomedullin.. Shionogi & Co, Kangawa Kenji, November 2, 1994: EP0622458-A2 (23 worldwide citation)

According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomed ...


3
Tanaka Shoji, Minamitake Yoshiharu, Kitajima Yasuo, Furuya Mayumi, Matsuo Hisayuki: Cnp analog peptides and their use.. Suntory, Matsuo Hisayuki, August 5, 1992: EP0497368-A1 (22 worldwide citation)

Novel peptides represented by the general formula: and physiologically acceptable acid addition salts thereof; where (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, H-Ser-Leu-Arg- ...


4
Sudoh Tetsuji C O Daiichi Pure, Maekawa Keiji C O Daiichi Phar, Minamino Naoto, Kangawa Kenji, Matsuo Hisayuki, Izumi Atsushi C O Daiichi Pure, Takashima Mika C O Daiichi Pur: Physiologically active polypeptide and dna.. Daiichi Pure Chemicals, Daiichi Seiyaku Co, Matsuo Hisayuki, September 5, 1990: EP0385476-A1 (11 worldwide citation)

A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus usefu ...


5
Matsuo Hisayuki, Kangawa Kenji: Peptide production and use thereof.. Suntory, Matsuo Hisayuki, July 3, 1985: EP0147193-A2 (10 worldwide citation)

A vasorelaxant substance obtainable in the beta -component (being fractions 42-45 as shown in Figure 3) resulting from:- extracting human atrium cordis by boiling in acetic acid and homogenising; cooling, homogenising and centrifuging the extract to obtain a supernatant; precipitating impurities fro ...


6
Ohsuye Kazuhiro, Kitano Katsuhiko, Tanaka Shoji, Matsuo Hisayuki, Mizuno Kensaku: Recombinant c-terminal alpha-amidating enzyme.. Suntory, Matsuo Hisayuki, January 18, 1989: EP0299790-A2 (8 worldwide citation)

A C-terminal alpha -amidating enzyme of Xenopus laevis and precursor thereof produced by a recombinant DNA technique; a DNA coding for the enzyme or precursor thereof; a plasmid containing the DNA; a host organism transformed with the plasmid; a process for production of the enzyme using the transfo ...


7
Matsuo Hisayuki, Kangawa Kenji, Minamino Naoto: Novel physiologically active porcine peptide (cnp-53).. Matsuo Hisayuki, January 15, 1992: EP0466174-A1 (7 worldwide citation)

A peptide composed of 53 amino acid residues represented by the following amino acid sequence: and derivatives thereof represented by the following amino acid sequence: wherein X is as shown in the specification, are disclosed. These polypeptides are novel and have natriuretic and hypotensive action ...


8

9

10
Matsuo Hisayuki, Mizuno Kenzaku: C-terminal alpha-amidating enzyme and process for production and use thereof.. Matsuo Hisayuki, December 16, 1987: EP0249412-A2 (4 worldwide citation)

C-terminal alpha -amidating enzyme preparations, including preparations AE-I, AE-II, AE-IIa and AE-IIb, from the skin of Xenopus laevis, wherein all components can convert a peptide having a glycine residue at its C-terminal to a C-terminal amidated peptide lacking the glycine residue, and have a co ...